Drug repurposing of adapalene for melanoma treatment

• Published in: Pharmaceutical patent analyst Vol. 11; no. 1; pp. 9 - 14
• Main Authors: Anaya-Ruiz, Maricruz, Perez-Santos, Martin
• Format: Journal Article
• Language: English
• Published: England Newlands Press Ltd 01-01-2022
• Subjects: Acne Vulgaris - drug therapy; adapalene; Adapalene - therapeutic use; cancer; Cell Line; Drug Repositioning; drug repurposing; Humans; melanoma; Melanoma - drug therapy; therapy; melanoma; cancer; drug repurposing; therapy; adapalene
• ISSN: 2046-8954; 2046-8962
• DOI: 10.4155/ppa-2021-0021

Cancer drug repurposing is an attractive approach that leads to savings in time and investment. Adapalene, the first medical application of which was for the treatment of acne, has been described as a repurposing drug for the treatment of various types of cancer. Patent application CN111329851 describes the use of adapalene for the treatment of melanoma, by assays carried out on melanoma cell lines. Adapalene demonstrated antiproliferative activity in melanoma cell lines via S-phase arrest-dependent apoptosis mediated by DNA damage through an increase in the expression of p-ATM and p-chk2 and a decrease in the expression of p-BRCA1 and Rad51. Even though no evidence on efficacy and efficiency is shown in preclinical and clinical studies, CN111329851 patent shows that adapalene may be a repurposing drug for the treatment of melanoma.